Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Remifentanil Noridem 2 mg powder for concentrate for solution for injection or infusion
Medicines register · Ireland

Remifentanil Noridem 2 mg powder for concentrate for solution for injection or infusion

Authorisation PA1122/014/002 · Noridem Enterprises Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Noridem Enterprises Limited (all products →)
Active substance
Remifentanil
Clinical trials
20 clinical trials →
Dosage form
Powder for concentrate for solution for injection/infusion
Route of administration
Intravenous use
ATC codes
N01AH, N01AH06
First authorised
21/12/2011
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Remifentanil: supply and approvals

9 authorised products on the HPRA list contain Remifentanil. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
Remifentanil Hydrochloride Injection: in shortage, updated 18 Nov 2026
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 14 years (since 21 December 2011). The HPRA list marks it as marketed in Ireland.

Other medicines with Remifentanil in Ireland

7 other products on the HPRA list contain Remifentanil, from 3 licence holders; 3 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Remifentanil Noridem 5 mg powder for concentrate for solution for injection or infusionNoridem Enterprises LimitedNational authorisation (PA)Marketed
Ultiva 2 mg Powder for Concentrate for Solution for InfusionAspen Pharma Trading LimitedNational authorisation (PA)Marketed
Ultiva 5 mg Powder for Concentrate for Solution for InfusionAspen Pharma Trading LimitedNational authorisation (PA)Marketed
Remifentanil 1 mg powder for concentrate for solution for injection or infusionFresenius Kabi Deutschland GmbHNational authorisation (PA)Not marketed
Remifentanil 2 mg powder for concentrate for solution for injection or infusionFresenius Kabi Deutschland GmbHNational authorisation (PA)Not marketed
Remifentanil 5 mg powder for concentrate for solution for injection or infusionFresenius Kabi Deutschland GmbHNational authorisation (PA)Not marketed
Remifentanil Noridem 1 mg powder for concentrate for solution for injection or infusionNoridem Enterprises LimitedNational authorisation (PA)Not marketed

Other substances in ATC group N01AH

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group N01AH with this product:

FENTANYL CITRATE (3) · SUFENTANIL CITRATE (1) · ALFENTANIL HYDROCHLORIDE (1) · Remifentanil hydrochloride (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Noridem Enterprises Limited holds 70 products on the HPRA list, with 55 different active substances; 21 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.